论文部分内容阅读
目的观察吉西他滨联合顺铂(GP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法对89例经病理或细胞学证实的晚期非小细胞肺癌患者给予联合化疗,GP方案49例,NP方案40例,两组病例具有可比性。吉西他滨1000 mg/m2,静脉滴注第1、8天;顺铂25 mg/m2,静脉滴注,第1~3天;长春瑞滨25 mg/m2,静脉滴注,第1、8天。21 d为一个周期,每例患者治疗2周期以上。结果 GP组总有效率46.9%,NP组总有效率42.5%,差异无显著性(P>0.05)。最常见的毒副反应为骨髓抑制。GP组Ⅲ~Ⅳ度血小板减少发生率显著高于NP组(P<0.05),而NP组Ⅲ~Ⅳ度白细胞减少发生率显著高于GP组(P<0.05)。静脉炎发生率NP组显著高于GP组(P<0.05)。结论 GP方案与NP方案治疗晚期非小细胞肺癌(NSCLC)疗效肯定,毒性均可耐受。两方案疗效比较差异无显著性。
Objective To observe the efficacy and toxicity of gemcitabine combined with cisplatin (GP) and vinorelbine plus cisplatin (NP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 89 patients with pathologically or cytologically confirmed advanced non-small cell lung cancer were given chemotherapy. There were 49 cases of GP regimen and 40 cases of NP regimen. The two groups were comparable. Gemcitabine 1000 mg / m2, intravenous infusion of 1,8 days; cisplatin 25 mg / m2, intravenous infusion, the first 3 days; vinorelbine 25 mg / m2, intravenous infusion, the first 1,8 days. 21 d for a cycle, each patient treated more than two cycles. Results The total effective rate was 46.9% in GP group and 42.5% in NP group, with no significant difference (P> 0.05). The most common adverse reaction is myelosuppression. The incidence of grade Ⅲ ~ Ⅳ thrombocytopenia in GP group was significantly higher than that in NP group (P <0.05). The incidence of grade Ⅲ ~ Ⅳ leukopenia in NP group was significantly higher than that in GP group (P <0.05). The incidence of phlebitis in NP group was significantly higher than that in GP group (P <0.05). Conclusion GP and NP regimens are effective and can be tolerated in the treatment of advanced non-small cell lung cancer (NSCLC). No significant difference between the two programs efficacy.